4 years ago

Exscientia Secures $525 Million to Advance AI-Powered Drug Development

  • Exscientia, an Oxford-based pharmatech company using AI to design patient-based drugs, raised $225 million in Series D funding led by SoftBank Vision Fund 2

  • Existing investors Novo Holdings and Blackrock also participated

  • The round also includes an additional $300 million equity commitment from SoftBank that can be drawn at Exscientia's discretion

  • Exscientia plans to use the funds to advance its drug pipeline through clinical testing and expand its AI platform for autonomous drug design

  • The company's platform uses a combination of AI and experimental technologies to capture and utilize patient-relevant data for precision drug design.

      • ProblemHealthcare

      "Exscientia aims to address the challenge of designing patient-specific drugs using artificial intelligence (AI) to improve treatment outcomes."

      Solution

      "The company has developed a platform that integrates AI with experimental technologies to design precision drugs, optimizing them for multiple parameters based on patient data."

      Covered on